文献速递胸部CT

国家肺癌筛查试验中与新增实性结节相关的肺癌风险

Lung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial.
PubMed 文献 · AJR Am J Roentgenol · 2017-09-12

基于国家肺癌筛查试验中25002名接受基线及基线后两次年度低剂量CT筛查的受试者,放射科医师将基线后检出的结节分类为新增或原有。基线后两次筛查中每次均有2.6%受试者出现新增实性结节,肺癌风险随结节大小增加而升高,新增结节与基线结节在相同大小下肺癌风险存在差异。

要点

  • 基线后年度筛查中新增实性结节的发生率为每次2.6%。
  • 新增实性结节中53.0%为<6 mm,29.5%为6至<10 mm,17.1%为≥10 mm。
  • 新增结节相关肺癌风险从<4 mm的1.1%升至≥20 mm的24.0%。

核心结论

  • 新增结节年发生率为2-3%,肺癌风险随结节大小增加而升高;与基线结节相比,新增结节可能因大小不同而传递不同的肺癌风险。

研究设计与样本

  • 基于国家肺癌筛查试验,共25002名受试者接受基线低剂量CT筛查及基线后第1次(T1)或第2次(T2)年度低剂量CT筛查。

诊断标准与关键数值

  • 新增实性结节按平均直径分类:<6 mm占53.0%,6至<10 mm占29.5%,≥10 mm占17.1%。
  • 肺癌风险定义为基线后2年内诊断,从<4 mm结节的1.1%升至≥20 mm结节的24.0%。
  • 与基线实性结节相比,新增实性结节4至<6 mm(p<0.001)和6至<8 mm(p<0.001)的肺癌风险更高,而≥20 mm的新增结节风险更低(p=0.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: As low-dose CT (LDCT) lung cancer screening moves into routine clinical practice, evaluation of nodules identified as new becomes critical. We examine the frequency and clinical outcomes of new lung nodules reported at the two postbaseline annual screening examinations (hereafter referred to as postbaseline time 1 [T1] and time 2 [T2]), compared with those detected at baseline in the National Lung Screening Trial.

MATERIALS AND METHODS: Radiologists classified nodules detected at T1 and T2 as new or preexisting on the basis of comparison with findings from prior LDCT screening examinations. Subjects were tracked for lung cancer incidence and mortality. We examined the incidence of new nodules and their associated lung cancer risk by nodule size (i.e., mean diameter).

RESULTS: A total of 25,002 subjects underwent the baseline LDCT screening examination and either a T1 or T2 LDCT screen. At both T1 and T2, 2.6% of subjects had new solid nodules. Of the new solid nodules, 53.0% were < 6 mm, 29.5% were 6 to < 10 mm, and 17.1% were ≥ 10 mm. Lung cancer risk (defined as diagnosis within 2 years of baseline) increased from 1.1% for nodules < 4 mm to 24.0% for those ≥ 20 mm. Compared with solid nodules detected at baseline, the cancer risk was higher for new solid nodules that were 4 to < 6 mm (p < 0.001) and 6 to < 8 mm (p < 0.001) but lower for new nodules ≥ 20 mm (p = 0.03). Cancers associated with new nodules had significantly poorer survival than did those associated with baseline nodules and were significantly less likely to be adenocarcinoma.

CONCLUSION: The incidence of new nodules was 2-3% annually, with the cancer risk increasing by nodule size. New nodules may convey differential lung cancer risks by size, compared with baseline nodules.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Pinsky PF, Gierada DS, Nath PH, et al. Lung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial. AJR Am J Roentgenol. 2017. PMID: 28898131. doi:10.2214/AJR.17.18252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。